Head-to-head evidence
etrasimod vs tamuzimod
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Ulcerative Colitis
Shared mechanism: S1P receptor · full Ulcerative Colitis pipeline
etrasimod · Velsipity
Marketed by Pfizer
NCT03945188 · Phase 3 · completed
Randomized 2:1, double-blind, placebo-controlled, adequately powered (n=433) phase 3 trial with a hard clinical/endoscopic composite primary endpoint (clinical remission via modified Mayo score incorporating centrally-read endoscopy), and both co-primary endpoint comparisons reached statistical significance in the favorable direction (p<0.001), satisfying the 'strong' definition.
Next expected readout: June 2027 · NCT07782242 (registry estimate)
tamuzimod
Developed by Eli Lilly
NCT05156125 · Phase 2 · terminated
This was a randomized, quadruple-blind, placebo-controlled trial in 213 patients using clinical remission on the modified Mayo score, a validated disease-activity measure combining symptoms and endoscopy, as the primary endpoint. Both the 60 mg and 30 mg tamuzimod doses achieved significantly higher remission rates than placebo at week 13.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: etrasimod's landscape · tamuzimod's landscape